A high-purity gentianic acid and its application

By optimizing the catalyst and reaction temperature, and combining salt formation, free crystallization, and decolorization crystallization processes, the problems of low purity and high impurities of gentian acid have been solved, realizing the preparation and industrial production of high-purity gentian acid, which is suitable for the stability requirements of pharmaceutical excipients and injections.

CN123106414APending Publication Date: 2026-11-17BEIJING SINOTAU INT PHARMA TECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611109867.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-05-18
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In the existing technology, gentic acid has low purity and high impurity content, which makes it difficult to meet the requirements of pharmaceutical excipients, affects the stability and color properties of radioactive injection solutions, and has a low yield, making it difficult to achieve industrial production.

Method used

By optimizing the catalyst and reaction temperature, and combining salt formation, free crystallization, and decolorization crystallization processes, a method for preparing high-purity gentianic acid has been developed. The method includes feeding reaction, acidification, extraction, crystallization, salt formation, free crystallization, and decolorization crystallization steps, controlling the impurity content to below 0.1% and achieving a purity of 99.5%.

Benefits of technology

The preparation of high-purity gentic acid was achieved, with impurities controlled below 0.1% and a yield of 18-22%, suitable for large-scale industrial production. This ensures the quality of pharmaceutical excipients and the stability of injection solutions, and solves the problems of low purity and low yield in existing technologies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106414A_ABST
    Figure CN123106414A_ABST
Patent Text Reader

Abstract

This application discloses a high-purity gentianic acid with a purity ≥99.50%, comprising gentianic acid, salicylic acid, and impurity A, wherein the structural formula of impurity A is [not specified]. This application also discloses the application of the above-mentioned high-purity gentianic acid in the preparation of antiviral agents, antibacterial agents, analgesics, or antioxidant excipients. The high-purity gentianic acid of this application is obtained through a specific preparation method, and the yield of high-purity gentianic acid can reach 18-22%, suitable for large-scale industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the patent application filed on May 18, 2022, with application number CN202210537742.2 and titled "A High-Purity Gentian Acid and Its Application". Technical Field

[0002] This application relates to the pharmaceutical and chemical industries. Specifically, this application relates to a high-purity gentianic acid and its applications. Background Technology

[0003] Gentian acid, chemically known as 2,5-dihydroxybenzoic acid, also called 5-hydroxysalicylic acid, is a minor product of salicylic acid metabolism via the kidneys. Clinically, it is commonly used as an antiviral agent, antibacterial agent, and analgesic (sodium salt). Gentian acid belongs to the hydroquinone class of compounds and is prone to oxidation; therefore, it is also used as an antioxidant excipient in the pharmaceutical industry. Gentian acid is already used as a pharmaceutical excipient abroad.

[0004] Existing technologies use benzoic acid as a raw material to synthesize products through steps such as chlorination and hydrolysis. However, the main products synthesized by this method are five kinds, which are difficult to separate and purify, resulting in a final yield of only about 5%, making it difficult to achieve industrial production.

[0005] The current process mainly uses the Köber-Schmidt reaction of hydroquinone to prepare gentianic acid. However, the product obtained by this method contains a large number of isomers 2,4-dihydroxybenzoic acid and 2,6-dihydroxybenzoic acid. Not only is the product purity low, but it is also dark in color, appearing as a yellow powder crystal. Multiple recrystallization purifications are required to obtain a white gentianic acid product that meets the specifications. The yield is low and the cost is high.

[0006] Patent CN100363322C discloses a method for producing hydroxybenzoic acid compounds. This method includes preparing an alkali metal salt of a phenolic compound from a phenolic compound by reacting the alkali metal salt with carbon dioxide. The preparation of the alkali metal salt from the phenolic compound comprises the following steps: a) reacting an alkali metal alkoxide with an excess of a phenolic compound, wherein the phenolic compound is in excess of the alkali metal alkoxide, to form the alkali metal salt of the phenolic compound; and b) simultaneously with a) distilling off the alcohol formed in the reaction. This method does not use aprotic polar organic solvents.

[0007] Patent CN1684935A discloses a method for preparing hydroxybenzoic acids. The method involves dehydrating a phenol with an alkali metal compound to obtain an alkali metal salt of the phenol, then reacting the alkali metal salt with carbon dioxide to prepare the hydroxybenzoic acid. In this method, the alkali metal compound and an excess of phenol relative to the alkali metal compound undergo a dehydration reaction at a temperature of 160°C or higher. This invention does not use aprotic polar organic solvents, and the process is simple and inexpensive.

[0008] Patent CN102766042A discloses a method for preparing high-purity gentianic acid, comprising: adding salicylic acid and glacial acetic acid into a reaction vessel and stirring evenly; adding bromine dropwise after heating to obtain brominated salicylic acid, and recovering glacial acetic acid by vacuum distillation; adding liquid alkali in the presence of cuprous chloride, heating, and reacting to obtain hydroxysalicylic acid; cooling to room temperature, filtering to remove cuprous chloride, and adjusting the pH to 2; filtering out the hydroxysalicylic acid mixture and adding it to water, adjusting the pH to 6.9~7.1, cooling to crystallize and obtaining high-purity sodium gentianate; adding the obtained sodium gentianate to water, adjusting the pH to 2, and heating to reflux in the presence of activated carbon and oxalic acid; filtering, and cooling the filtrate to crystallize and obtain gentianic acid.

[0009] The gentic acid products obtained by the aforementioned existing methods all exhibit poor purity and low yields. This makes it difficult to maintain the stability of radioactive injections within their shelf life when gentic acid is used as an excipient in the preparation of injectable formulations, and it is impossible to guarantee the stability of radiochemical purity, injection color, and physicochemical properties. As a key stabilizer for radioactive injectable drugs, the solubility of gentic acid is crucial. Currently, it is difficult to find gentic acid on the market that meets these requirements. Summary of the Invention

[0010] In order to overcome the shortcomings of the existing technology, this application, based on the existing technology, screens catalysts and bases, optimizes reaction temperature, etc., and develops subsequent salt formation, free crystallization, decolorization and crystallization processes for products with low purity and high impurity content, so as to finally obtain a qualified high-purity gentian acid.

[0011] The specific technical solution of this application is as follows: 1. A high-purity gentianic acid, characterized in that its purity is ≥99.50%, comprising: gentianic acid, salicylic acid, and impurity A, wherein the impurity A has the structure shown in formula (I): Formula (I); Preferably, in the high-purity gentianic acid, the mass percentage of salicylic acid is ≤0.1%, and the mass percentage of impurity A is ≤0.1%. Preferably, the high-purity gentianic acid further comprises impurity B, wherein impurity B has the structure shown in formula (II): Formula (II); Preferably, in the high-purity gentianic acid, the mass percentage of impurity B is ≤0.1%.

[0012] 2. The high-purity gentianic acid according to claim 1, characterized in that it is prepared by a method comprising the following steps: Feeding reaction: 5-bromosalicylic acid is added to an inorganic alkaline solution for reaction; Acidification: Add concentrated hydrochloric acid to adjust the pH, precipitate the solid, and filter; Extraction: Add extractant one to the filtrate obtained from the acidification step, extract, and after standing, flocculent matter appears; Filtration: Filtration and separation are performed to obtain organic phase one and aqueous phase. Extractant two is added to the aqueous phase for extraction. Filtration and separation are performed again to obtain organic phase two. Organic phase two is combined with organic phase one to obtain organic phase three. Crystallization: Concentrate organic phase III to precipitate solid, add organic solvent I to obtain crude gentianic acid; Salt formation: Add crude gentianic acid to organic solvent II, and add dropwise a solution of organic solvent II containing an organic base to obtain wet gentianic acid organic base salt; Free: Add the wet product of gentianic acid organic base salt to water, add concentrated hydrochloric acid dropwise to adjust the pH, filter, and obtain the wet product of gentianic acid refining; Decolorization and crystallization: Add the wet product of gentianic acid concentrate and the decolorizing agent to water, filter, and obtain gentianic acid crystals; Filtration and drying: Gentian acid crystals were rinsed with water, then washed with an organic solvent, and dried to obtain high-purity gentian acid.

[0013] 3. The high-purity gentianic acid according to item 2, characterized in that, in the feeding reaction step, 5-bromosalicylic acid is added to an inorganic alkaline solution in the presence of a copper catalyst, stirred, heated to react 5-bromosalicylic acid with the inorganic alkaline solution, then cooled and water is added; Preferably, the inorganic alkaline solution is an aqueous solution of sodium hydroxide or an aqueous solution of potassium hydroxide, and more preferably an aqueous solution of potassium hydroxide. Preferably, the concentration of the inorganic alkaline solution is 4~8 mol / L, more preferably 5~6 mol / L; Preferably, the molar ratio of the inorganic base to 5-bromosalicylic acid is 4~7:1, more preferably 5~6:1; Preferably, the temperature is increased to 90~114℃, more preferably to 105~114℃; Preferably, the reaction of 5-bromosalicylic acid with an inorganic alkaline solution is carried out by heating, and the content of 5-bromosalicylic acid is controlled to be less than 1.5% in HPLC. The reaction time is 20-48 h, more preferably 20-30 h. Preferably, the temperature reduction is to 20~30℃; Preferably, 5-bromosalicylic acid is added to an inorganic alkaline solution in the presence of a copper catalyst and oxalic acid; more preferably, the molar ratio of oxalic acid to 5-bromosalicylic acid is 0.05~0.15:1. Preferably, the copper catalyst is copper sulfate pentahydrate or cuprous oxide, more preferably copper sulfate pentahydrate; preferably, the molar ratio of copper sulfate pentahydrate to 5-bromosalicylic acid is 0.05~0.15:1; preferably, the molar ratio of cuprous oxide to 5-bromosalicylic acid is 0.025~0.075:1.

[0014] Preferably, the molar ratio of water to 5-bromosalicylic acid is 40-70:1, more preferably 50-60:1.

[0015] 4. The high-purity gentianic acid according to item 2 or 3, characterized in that, in the acidification step, the pH is adjusted to 2.3 to 2.5; Preferably, concentrated hydrochloric acid is added at 20-30°C to adjust the pH.

[0016] 5. The high-purity gentianic acid according to any one of items 2 to 4, characterized in that, in the extraction step, the extractant is selected from any one or more of dichloromethane, ethyl acetate, isopropyl acetate, toluene and methyl tert-butyl ether; Preferably, the extractant is methyl tert-butyl ether; Preferably, in the extraction step, extractant one and extraction aid are added to the filtrate obtained in the acidification step, wherein the extraction aid is preferably sodium chloride; Preferably, the mass ratio of methyl tert-butyl ether to 5-bromosalicylic acid is 4~6:1, more preferably 5~5.5:1; Preferably, the mass ratio of sodium chloride to 5-bromosalicylic acid is 1.0~1.5:1; Preferably, in the filtration step, the extractant is selected from any one or more of dichloromethane, ethyl acetate, isopropyl acetate, toluene, and methyl tert-butyl ether; Preferably, the mass ratio of the extractant to 5-bromosalicylic acid is 4~6:1, more preferably 5~5.5:1; Preferably, a filter aid is added to the funnel, and the mixture is filtered and separated to obtain an organic phase and an aqueous phase; more preferably, the filter aid is diatomaceous earth.

[0017] 6. The high-purity gentianic acid according to any one of items 2 to 5, characterized in that, in the crystallization step, the organic phase III is concentrated, a solid is precipitated, an organic solvent I is added, the mixture is stirred, filtered, and the filter cake is dried to obtain crude gentianic acid; Preferably, the organic solvent is selected from one or more of n-heptane, acetone, ethyl acetate, petroleum ether, and chloroform; Preferably, a large amount of solid is precipitated from the concentrated organic phase; Preferably, the organic phase III is concentrated under reduced pressure at 40~60°C, more preferably at 40~50°C; Preferably, the mass ratio of the organic solvent to 5-bromosalicylic acid is 4~5.5:1, more preferably 4.5~5:1; Preferably, the stirring time is 1-2 hours; Preferably, filtration is performed at 20~30℃; Preferably, the filter cake is vacuum dried at 40-50°C for 2-4 hours to obtain crude gentianic acid.

[0018] 7. The high-purity gentianic acid according to any one of items 2 to 6, characterized in that, in the salt formation step, crude gentianic acid is added to organic solvent II, stirred, a solution of organic solvent II containing an organic base is added dropwise, cooled, and filtered to obtain wet gentianic acid organic base salt; Preferably, a solution of organic solvent II containing an organic base is added dropwise at a temperature of 10~35℃; Preferably, the organic base is diethylamine; Preferably, the molar ratio of the organic base to 5-bromosalicylic acid is 0.75~0.85:1; Preferably, the mass ratio of the organic solvent II to the crude gentian acid is 8.6~10:1, more preferably 9~9.8:1; Preferably, the organic solvent is selected from one or more of acetone, isopropanol, and tetrahydrofuran; Preferably, the temperature is reduced to 2-8°C.

[0019] 8. The high-purity gentianic acid according to any one of items 2 to 7, characterized in that, in the freeing step, the wet product of gentianic acid organic base salt is added to water, stirred, concentrated hydrochloric acid is added dropwise to adjust the pH, cooled, and filtered to obtain the wet product of refined gentianic acid. Preferably, concentrated hydrochloric acid is added dropwise at 20-30°C to adjust the pH. Preferably, the pH is adjusted to 1-2; Preferably, the mass ratio of water to the wet product of gentianic acid organic base salt is 4~6:1; Preferably, the cooling is reduced to 0~10℃.

[0020] 9. The high-purity gentianic acid according to any one of items 2 to 8, characterized in that, in the decolorization and crystallization step, the wet product of gentianic acid refining and the decolorizing agent are added to water, stirred, heated, filtered, and the filtrate is cooled to obtain gentianic acid crystals; Preferably, the gentian acid refined product (wet), decolorizing agent, and oxalic acid are added to water; Preferably, the decolorizing agent is selected from one or more of activated carbon, alumina, and kaolin; Preferably, the temperature is maintained for 0.5 to 6 hours after heating, more preferably 0.5 to 4 hours, and even more preferably 0.5 to 1.5 hours. Preferably, the temperature is increased to 65~75°C; Preferably, the mass ratio of activated carbon to wet gentian acid concentrate is 0.05~0.1:1; Preferably, the mass ratio of the oxalic acid to the gentianic acid refined wet product is 0.01~0.03:1; Preferably, the mass ratio of water to the wet product of gentian acid is 4-6:1; Preferably, the solution is filtered and the filtrate is cooled to 0-10°C to obtain gentianic acid crystals.

[0021] 10. The high-purity gentianic acid according to any one of items 2 to 9, characterized in that, in the filtration and drying step, the drying conditions are: 40-55°C, vacuum drying for 10-15 hours.

[0022] 11. The use of high-purity gentianic acid according to any one of items 1 to 10 in the preparation of antiviral agents, antibacterial agents, analgesics or antioxidant excipients.

[0023] The effects of the invention The high-purity gentianic acid of this application has a purity controlled above 99.5%, and various organic impurities can be controlled below 0.1%, making it suitable for pharmaceutical excipients. The process of this application ensures the quality of gentianic acid; organic impurities do not alter its crystallization habit, do not form eutectics, and do not reduce its apparent solubility in water. The color of gentianic acid affects the color of the injection solution; however, the organic impurities in the gentianic acid obtained by the process of this application do not affect the color of the injection solution. Furthermore, it solves the problem that in radiopharmaceuticals, when gentianic acid is used in combination with vitamin C, the presence of organic impurities can disrupt the intermolecular solubility balance under complex system conditions. Moreover, the high-purity gentianic acid of this application is obtained through a specific preparation method, with a yield of 18-22%, suitable for large-scale industrial production. Detailed Implementation

[0024] The following description illustrates exemplary embodiments of this application, including various details to aid understanding; however, these should be considered merely exemplary. Therefore, those skilled in the art will recognize that various changes and modifications can be made to the embodiments described herein without departing from the scope and spirit of this application. Similarly, for clarity and brevity, descriptions of well-known functions, structures, and reagents are omitted in the following description.

[0025] This application provides a high-purity gentianic acid, characterized in that its purity is ≥99.5%, and it comprises: gentianic acid, salicylic acid, and impurity A. Wherein, impurity A has the structure shown in formula (I): Formula (I).

[0026] In one specific embodiment, the high-purity gentianic acid contains salicylic acid at a mass percentage of ≤0.1%, for example, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, etc., and impurity A at a mass percentage of ≤0.1%, for example, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, etc.

[0027] In one specific embodiment, the high-purity gentianic acid comprises: gentianic acid, salicylic acid, impurity A, and impurity B, wherein impurity B has the structure shown in formula (II): Equation (II).

[0028] In one specific embodiment, the mass percentage of impurity B in the high-purity gentianic acid is ≤0.1%, for example, it can be 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, etc.

[0029] In one specific embodiment, the high-purity gentianic acid comprises gentianic acid, salicylic acid, and impurity A, but does not contain impurity B.

[0030] In one specific embodiment, the high-purity gentianic acid contains impurity C (2,3-dihydroxybenzoic acid), and the mass percentage of 2,3-dihydroxybenzoic acid in the high-purity gentianic acid is ≤0.1%, for example, it can be 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, etc.

[0031] The "gentisic acid" in this application has the English name: Gentisic Acid, the chemical name: 2,5-dihydroxybenzoic acid, the CAS number: 490-79-9, and other names: DHB, 5-hydroxysalicylic acid. Its molecular formula is C7H6O4, and its molecular weight is 154.12. It is a white to pale yellow powder, readily soluble in methanol, soluble in acetonitrile, slightly soluble in water, and has a melting point of 207~210℃. Gentisic acid is used as a pharmaceutical excipient, acting as a free radical quencher in formulations to reduce the radioactive self-decomposition effect of radionuclides on prodrugs.

[0032] In one specific embodiment, the high-purity gentianic acid of this application is prepared by a method comprising the following steps: (1) Feeding reaction: 5-bromosalicylic acid is added to an inorganic base and catalyst solution for reaction; (2) Acidification: Add concentrated hydrochloric acid to adjust the pH, precipitate the solid, and filter; (3) Extraction: Add extractant one to the filtrate obtained from the acidification step, extract, and flocculent matter appears after standing. (4) Filtration: Filtration and separation are performed to obtain organic phase one and aqueous phase. Extractant two is added to the aqueous phase for extraction. Filtration and separation are performed again to obtain organic phase two. Organic phase two is combined with organic phase one to obtain organic phase three. (5) Crystallization: Concentrate organic phase III to precipitate solid, add organic solvent I to obtain crude gentianic acid; (6) Salt formation: Add crude gentianic acid to organic solvent II, and add dropwise a solution of organic solvent II containing organic base to obtain wet gentianic acid organic base salt; (7) Free: Add the wet product of gentianic acid organic base salt to water, add concentrated hydrochloric acid to adjust the pH, filter, and obtain the wet product of gentianic acid refined product; (8) Decolorization and crystallization: Add the wet product of gentian acid and the decolorizing agent to the crystallization solvent water, filter, and obtain the gentian acid product; (9) Filtration and drying: The gentian acid product is rinsed with water and then washed with an organic solvent and dried to obtain high-purity gentian acid.

[0033] The “5-bromosalicylic acid” in this application has the English name: 5-Bromosalicylic acid, and other chemical names: 5-bromo-2-hydroxybenzoic acid. Its CAS number is 89-55-4, its molecular formula is C7H5BrO3, and its molecular weight is 217.02. Calculated on anhydrous basis, it contains not less than 98.0% C7H5BrO3. It is a white or off-white crystalline powder.

[0034] In one specific embodiment, during the feeding reaction step, 5-bromosalicylic acid is added to an inorganic alkaline solution in the presence of a copper catalyst, stirred, heated to allow the 5-bromosalicylic acid to react with the inorganic alkaline solution, then cooled and water is added.

[0035] In one specific embodiment, in the feeding reaction step, the inorganic alkaline solution is an aqueous solution of sodium hydroxide or potassium hydroxide, preferably an aqueous solution of potassium hydroxide; the concentration of the inorganic alkaline solution is 4~8 mol / L, for example, it can be 4 mol / L, 4.5 mol / L, 5 mol / L, 5.5 mol / L, 6 mol / L, 6.5 mol / L, 7 mol / L, 7.5 mol / L, 8 mol / L, etc. The lower the concentration of the inorganic alkaline solution, the slower the reaction. Considering cost and ease of operation, an inorganic alkaline solution of 5~6 mol / L is preferred.

[0036] In one specific embodiment, in the feeding reaction step, the molar ratio of the inorganic base to 5-bromosalicylic acid is 4 to 7:1, for example, it can be 4:1, 4.5:1, 5:1, 5.3:1, 5.5:1, 6:1, 6.5:1, 7:1, etc., preferably 5 to 6:1.

[0037] In one specific embodiment, during the feeding reaction step, the temperature rise is to 0~114℃, for example, 90℃, 100℃, 101℃, 102℃, 103℃, 104℃, 105℃, 106℃, 107℃, 108℃, 109℃, 110℃, 111℃, 112℃, 113℃, 114℃, etc., preferably to 105~114℃. 114℃ is the boiling point of the reaction system, and it is impossible to raise the temperature to a higher level. By controlling the temperature within this range, the reaction time is short and the raw material conversion is complete.

[0038] In one specific embodiment, during the reaction step, the temperature is increased to react 5-bromosalicylic acid with an inorganic alkaline solution. The HPLC analysis shows that the content of 5-bromosalicylic acid is less than 1.5%, and the reaction time is 20–48 h, for example, 20 h, 22 h, 24 h, 26 h, 28 h, 30 h, 32 h, 34 h, 36 h, 38 h, 40 h, 42 h, 44 h, 46 h, 48 h, etc., preferably 20–30 h. Controlling the reaction time within this range ensures complete reaction and minimizes impurities.

[0039] In one specific embodiment, the method for controlling the content of 5-bromosalicylic acid by HPLC in the feeding reaction step includes the following steps: 5-Bromosylacrylic acid positioning solution: Take an appropriate amount of 5-bromosylacrylic acid reference standard, add solvent to dissolve and dilute to prepare a solution containing about 6 μg per 1 mL, and shake well; Test solution: Take an appropriate amount of the reaction solution, dilute it 400 times with solvent (e.g., dilute 0.025 mL to 10 mL), shake well, filter, and take the filtrate; Chromatographic conditions: Octadecylsilane-bonded silica gel (Thermo Acclaim 120 Å C18, 4.6 mm × 250 mm, 5 μm, or a column of equivalent performance) was used as the packing material; 0.05% phosphoric acid aqueous solution was used as mobile phase A, and acetonitrile was used as mobile phase B; the trapping column was a Welch Ghost-Buster Column II 4.0 × 50 mm or other suitable trapping column; the flow rate was 1.0 mL per minute, with linear gradient elution; the column temperature was 40 °C; the detection wavelength was 220 nm; and the injection volume was 10 μL. Determination method: Accurately measure the test solution and inject it into the liquid chromatograph, and record the chromatogram; In the chromatogram of the limit test solution, the peak area of ​​5-bromosalicylic acid, calculated by the area normalization method, shall not exceed 1.5% of the total peak area.

[0040] In one specific embodiment, during the feeding reaction step, the cooling is reduced to 20~30℃, for example, 20℃, 21℃, 22℃, 23℃, 24℃, 25℃, 26℃, 27℃, 28℃, 29℃, 30℃, etc.

[0041] In one specific embodiment, during the feeding reaction step, 5-bromosalicylic acid is added to an inorganic alkaline solution in the presence of a copper catalyst and oxalic acid. Oxalic acid is used as an antioxidant and is readily soluble in water for removal.

[0042] In one specific embodiment, during the feeding reaction step, the molar ratio of oxalic acid to 5-bromosalicylic acid is 0.05~0.15:1, for example, it can be 0.05:1, 0.06:1, 0.07:1, 0.08:1, 0.09:1, 0.1:1, 0.11:1, 0.12:1, 0.13:1, 0.14:1, 0.15:1, etc. Controlling the oxalic acid content within the above range results in a high product yield.

[0043] In one specific embodiment, in the feeding reaction step, the copper catalyst is copper sulfate pentahydrate or cuprous oxide. Since copper sulfate is soluble in water, post-processing is convenient, and the reaction can be more thorough, copper sulfate pentahydrate is the most preferred.

[0044] In one specific embodiment, during the feeding reaction step, the copper catalyst is copper sulfate pentahydrate, and the molar ratio of copper sulfate pentahydrate to 5-bromosalicylic acid is 0.05~0.15:1, for example, 0.05:1, 0.06:1, 0.07:1, 0.08:1, 0.09:1, 0.1:1, 0.11:1, 0.12:1, 0.13:1, 0.14:1, 0.15:1, etc. Controlling the copper sulfate pentahydrate content within the above range results in a shorter reaction time, higher conversion rate, and complete dissolution of the copper sulfate pentahydrate.

[0045] In one specific embodiment, in the feeding reaction step, the copper catalyst is cuprous oxide, and the molar ratio of cuprous oxide to 5-bromosalicylic acid is 0.025~0.075:1, for example, it can be 0.025:1, 0.03:1, 0.035:1, 0.04:1, 0.045:1, 0.05:1, 0.055:1, 0.06:1, 0.065:1, 0.07:1, 0.075:1, etc.

[0046] In one specific embodiment, during the feeding reaction step, the molar ratio of water to 5-bromosalicylic acid is 40-70:1, for example, it can be 40:1, 41.2:1, 42:1, 44:1, 46:1, 48:1, 50:1, 52:1, 54:1, 54.9:1, 55:1, 56:1, 58:1, 60:1, 62:1, 64:1, 66:1, 68:1, 68.6:1, 70:1, etc., preferably 50-60:1.

[0047] In one specific embodiment, during the acidification step, the pH is adjusted to 2.3-2.5, for example, 2.3, 2.35, 2.4, 2.45, 2.5, etc. Controlling the pH within this range can effectively remove salicylic acid, resulting in a higher yield, and minimizing pigment impurities in subsequent methyl tert-butyl ether extraction, leading to a lighter product color.

[0048] In one specific embodiment, during the acidification step, concentrated hydrochloric acid is added at 20-30°C to adjust the pH. For example, concentrated hydrochloric acid can be added at 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, etc. to adjust the pH.

[0049] In one specific embodiment, during the extraction step, the extractant is selected from any one or more of dichloromethane, ethyl acetate, isopropyl acetate, toluene, and methyl tert-butyl ether; preferably methyl tert-butyl ether.

[0050] In one specific embodiment, during the extraction step, the mass ratio of methyl tert-butyl ether to 5-bromosalicylic acid is 4~6:1, for example, it can be 4:1, 4.1:1, 4.2:1, 4.3:1, 4.4:1, 4.44:1, 4.5:1, 4.6:1, 4.7:1, 4.8:1, 4.9:1, 5:1, 5.1:1, 5.18:1, 5.2:1, 5.3:1, 5.4:1, 5.5:1, 5.6:1, 5.7:1, 5.8:1, 5.92:1, 6:1, etc., preferably 5~5.5:1.

[0051] In one specific embodiment, during the extraction step, the mass ratio of sodium chloride to 5-bromosalicylic acid is 1.0 to 1.5:1, for example, it can be 1.0:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, etc.

[0052] In one specific embodiment, during the filtration step, the extractant is selected from any one or more of dichloromethane, ethyl acetate, isopropyl acetate, toluene, and methyl tert-butyl ether.

[0053] In one specific embodiment, during the filtration step, the mass ratio of the extractant II to 5-bromosalicylic acid is 4~6:1, for example, it can be 4:1, 4.1:1, 4.2:1, 4.3:1, 4.4:1, 4.44:1, 4.5:1, 4.6:1, 4.7:1, 4.8:1, 4.9:1, 5:1, 5.1:1, 5.18:1, 5.2:1, 5.3:1, 5.4:1, 5.5:1, 5.6:1, 5.7:1, 5.8:1, 5.92:1, 6:1, etc., preferably 5~5.5:1.

[0054] In one specific embodiment, during the filtration step, diatomaceous earth is added to the Buchner funnel, and the mixture is filtered and separated to obtain an organic phase and an aqueous phase.

[0055] In one specific embodiment, during the crystallization step, organic phase three is concentrated, a solid is precipitated, organic solvent one is added, the mixture is stirred, filtered, and the filter cake is dried to obtain crude gentian acid; wherein organic solvent one is selected from one or more of n-heptane, acetone, ethyl acetate, petroleum ether, and dichloromethane.

[0056] In one specific embodiment, during the crystallization step, the organic phase is concentrated under reduced pressure at a temperature of 40-60°C, for example, 40°C, 42°C, 44°C, 46°C, 48°C, 50°C, 52°C, 54°C, 56°C, 58°C, 60°C, etc., preferably at 40-50°C, to precipitate a large amount of solid. Controlling the temperature within this range results in high product purity and a shorter concentration time.

[0057] In one specific embodiment, during the crystallization step, the mass ratio of the organic solvent to 5-bromosalicylic acid is 4~5.5:1, for example, it can be 4:1, 4.08:1, 4.1:1, 4.2:1, 4.3:1, 4.4:1, 4.5:1, 4.6:1, 4.7:1, 4.8:1, 4.9:1, 5:1, 5.1:1, 5.2:1, 5.3:1, 5.44:1, 5.5:1, etc., preferably 4.5~5:1.

[0058] In one specific embodiment, during the crystallization step, the stirring time is 1-2 hours, for example, 1 hour, 1.1 hours, 1.2 hours, 1.3 hours, 1.4 hours, 1.5 hours, 1.6 hours, 1.7 hours, 1.8 hours, 1.9 hours, 2 hours, etc.; and the filtration is carried out at 20-30°C, for example, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, etc.

[0059] In one specific embodiment, during the crystallization step, the filter cake is vacuum dried at 40-50°C for 2-4 hours to obtain crude gentianic acid. For example, it can be vacuum dried at 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C for 2 hours, 2.2 hours, 2.4 hours, 2.6 hours, 2.8 hours, 3 hours, 3.2 hours, 3.4 hours, 3.6 hours, 3.8 hours, and 4 hours, respectively.

[0060] Solvent crystallization alone cannot effectively purify gentianic acid, which has a carboxylic acid structure. Therefore, this application develops a salt formation step and a free step.

[0061] In one specific embodiment, in the salt formation step, crude gentianic acid is added to organic solvent II, stirred, and a solution containing organic base in organic solvent II is added dropwise. The mixture is then cooled and filtered to obtain wet gentianic acid organic base salt.

[0062] In one specific embodiment, during the salt formation step, a solution of organic solvent II containing an organic base is added dropwise at temperatures ranging from 10 to 35°C, for example, 10°C, 12°C, 14°C, 15°C, 18°C, 20°C, 22°C, 25°C, 27°C, 30°C, 32°C, 34°C, and 35°C. By controlling the temperature within this range, subsequent cooling and crystal precipitation is less prone to explosive precipitation and results in fewer impurities.

[0063] In one specific embodiment, in the salt formation step, the organic base is diethylamine, and the organic solvent is selected from one or more of acetone, isopropanol, and tetrahydrofuran.

[0064] In one specific embodiment, during the salt-forming step, the molar ratio of the organic base to 5-bromosalicylic acid is 0.75 to 0.85:1, for example, it can be 0.75:1, 0.76:1, 0.77:1, 0.78:1, 0.79:1, 0.8:1, 0.81:1, 0.82:1, 0.83:1, 0.84:1, 0.85:1, etc., preferably 0.75 to 0.81:1. Controlling the organic base content within the above range ensures sufficient salt formation and fewer impurities.

[0065] In one specific embodiment, during the salt-forming step, the mass ratio of the organic solvent II to the crude gentianic acid is 8.6 to 10:1, for example, it can be 8.6:1, 8.7:1, 8.8:1, 8.9:1, 9:1, 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.42:1, 9.5:1, 9.6:1, 9.7:1, 9.8:1, 9.9:1, 10:1, etc., preferably 9 to 9.8:1. Controlling acetone within the above range can result in a higher yield and more complete dissolution of the crude gentianic acid.

[0066] In one specific embodiment, during the salt formation step, the cooling is reduced to 2-8°C, for example, to 2°C, 2.5°C, 3°C, 3.5°C, 4°C, 4.5°C, 5°C, 5.5°C, 6°C, 6.5°C, 7°C, 7.5°C, 8°C, etc. Controlling the temperature within the above range can achieve higher purity and yield.

[0067] In one specific embodiment, after the solution containing organic base and organic solvent II is added dropwise during the salt formation step, the solution is kept at a constant temperature for 0.3 to 0.8 hours, and then cooled down. For example, the solution can be kept at a constant temperature for 0.3 hours, 0.4 hours, 0.5 hours, 0.6 hours, 0.7 hours, 0.8 hours, etc.

[0068] In one specific embodiment, during the salt formation step, the cooling gradient is 15~25℃ / h, for example, it can be 15℃ / h, 17℃ / h, 19℃ / h, 20℃ / h, 22℃ / h, 23℃ / h, 25℃ / h, etc.

[0069] In one specific embodiment, during the salt formation step, the temperature is maintained for 0.3 to 0.8 hours after cooling, followed by filtration. For example, the temperature can be maintained for 0.3 hours, 0.4 hours, 0.5 hours, 0.6 hours, 0.7 hours, or 0.8 hours.

[0070] In one specific embodiment, during the leaching step, the wet product of gentianic acid organic base salt is added to water, stirred, concentrated hydrochloric acid is added dropwise to adjust the pH, cooled, and filtered to obtain the wet product of refined gentianic acid.

[0071] In one specific embodiment, during the ionization step, concentrated hydrochloric acid is added dropwise at 20-30°C to adjust the pH. For example, concentrated hydrochloric acid can be added dropwise at 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, etc.

[0072] In one specific embodiment, during the gentic acid release step, the pH is adjusted to 1-2, for example, to 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2. Maintaining the pH within this range allows for more complete gentic acid release and a higher product yield.

[0073] In one specific embodiment, during the freeing step, the mass ratio of water to the wet gentianic acid organic base salt is 4-6:1, for example, 4:1, 4.2:1, 4.4:1, 4.6:1, 4.8:1, 5:1, 5.2:1, 5.4:1, 5.6:1, 5.8:1, 6:1, etc. Controlling the water content within this range ensures complete dissolution of the wet gentianic acid organic base salt and results in a higher product yield.

[0074] In one specific embodiment, during the ionization step, the cooling is reduced to 0~10℃, for example, it can be 0℃, 1℃, 2℃, 3℃, 4℃, 5℃, 6℃, 7℃, 8℃, 9℃, 10℃, etc., and the cooling gradient is 15~25℃ / h, for example, it can be 15℃ / h, 17℃ / h, 19℃ / h, 20℃ / h, 22℃ / h, 23℃ / h, 25℃ / h, etc.

[0075] In one specific embodiment, during the ionization step, the temperature is maintained for 0.3 to 0.8 hours after cooling, followed by filtration. For example, the temperature can be maintained for 0.3 hours, 0.4 hours, 0.5 hours, 0.6 hours, 0.7 hours, or 0.8 hours.

[0076] In one specific embodiment, in the decolorization and crystallization step, the wet product of gentian acid and the decolorizing agent are added to water, stirred, heated, filtered, and the filtrate is cooled to obtain gentian acid crystals; the decolorizing agent is not limited to one or more of activated carbon, alumina, and kaolin.

[0077] In one specific embodiment, during the decolorization and crystallization steps, the wet product of refined gentian acid, the decolorizing agent, and oxalic acid are added to water, with oxalic acid acting as an antioxidant.

[0078] In one specific embodiment, during the decolorization and crystallization steps, the temperature is raised and then maintained for 0.5 to 6 hours, for example, 0.5 hours, 0.6 hours, 0.7 hours, 0.8 hours, 0.9 hours, 1 hour, 1.2 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 5.5 hours, 6 hours, etc., preferably 0.5 to 1.5 hours. Controlling the holding time within this range allows for complete dissolution of the wet gentian acid product and further controls the content of impurity B.

[0079] In one specific embodiment, during the decolorization and crystallization steps, the temperature is raised to 65-75°C, for example, to 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, etc. Controlling the temperature within this range ensures complete dissolution of the wet gentian acid product and improves the purity of the final product.

[0080] In one specific embodiment, during the decolorization and crystallization steps, the mass ratio of activated carbon to the wet gentian acid product is 0.05~0.1:1, for example, 0.05:1, 0.06:1, 0.07:1, 0.08:1, 0.09:1, 0.1:1, etc. Controlling the mass ratio of activated carbon to the wet gentian acid product within this range can improve the pigment removal efficiency.

[0081] In one specific embodiment, during the decolorization and crystallization steps, the mass ratio of the oxalic acid to the gentian acid refined wet product is 0.01~0.03:1, for example, it can be 0.01:1, 0.015:1, 0.02:1, 0.025:1, 0.03:1, etc.

[0082] In one specific embodiment, during the decolorization and crystallization steps, the mass ratio of water to the wet gentian acid product is 4-6:1, for example, 4:1, 4.2:1, 4.4:1, 4.6:1, 4.8:1, 5:1, 5.2:1, 5.4:1, 5.6:1, 5.8:1, 6:1, etc. Controlling the mass ratio of water to the wet gentian acid product within this range can improve the yield of the wet gentian acid product.

[0083] In one specific embodiment, during the decolorization and crystallization steps, the solution is filtered and cooled to 0~10℃, for example, 0℃, 1℃, 2℃, 3℃, 4℃, 5℃, 6℃, 7℃, 8℃, 9℃, 10℃, etc., and kept at this temperature for 0.3~0.8h, for example, 0.3h, 0.4h, 0.5h, 0.6h, 0.7h, 0.8h, etc., to obtain gentianic acid crystals.

[0084] In one specific embodiment, in the filtration and drying step, the drying conditions are: vacuum drying at 40~55℃ for 10~15h, for example, vacuum drying at 40℃, 42℃, 44℃, 46℃, 48℃, 50℃, 52℃, 54℃, 55℃, etc. for 10h, 11h, 12h, 13h, 14h, 15h, etc.

[0085] In one specific embodiment, all stirring in this application is carried out under nitrogen protection.

[0086] In one specific embodiment, the water is purified water.

[0087] This application also provides the use of the high-purity gentianic acid described in any of the above claims in the preparation of antiviral agents, antibacterial agents, analgesics, or antioxidant excipients.

[0088] Example This application provides a general and / or specific description of the materials and test methods used in the experiment. In the following embodiments, materials or instruments whose manufacturers are not specified are all conventional materials or instruments that can be obtained commercially.

[0089] Example 1 Feeding and reaction: Add 5.0 mol / L NaOH solution, 50 g of 5-bromosalicylic acid, 0.5 g of cuprous iodide, and 0.5 g of oxalic acid to the reactor; start stirring under nitrogen protection; heat to 100~120℃ and react for 24 h; take a sample and control the HPLC (5-bromosalicylic acid) ≤1.5%; cool down to 20~30℃ and add water; Acidification: Control the temperature at 20~30℃, add concentrated hydrochloric acid to adjust the pH of the reaction solution to (2.4), solid will precipitate out, filter; Extraction: Add 50g of sodium chloride and 250g of methyl tert-butyl ether to the filtrate, stir and extract, and flocculent matter will appear after standing. Filtration: Add 5g of diatomaceous earth to the Buchner funnel, filter, separate the liquid to obtain organic phase one and aqueous phase; add 125g of methyl tert-butyl ether to the aqueous phase, filter, separate the liquid to obtain organic phase two, and combine organic phase two with organic phase one to obtain organic phase three; Crystallization: Concentrate the organic phase under reduced pressure at 40-50℃ until a large amount of solid precipitates out. Add 360g of n-heptane; stir for 1-2 hours; filter at room temperature (20-30℃); dry the filter cake under vacuum at 40-50℃ for 2-4 hours to obtain 16g of crude gentianic acid. Salt formation: Add 250g of acetone to the reaction vessel, add crude gentianic acid, and start stirring under nitrogen protection; control the temperature at 10~35℃, add 36g of acetone solution containing 13.15g of diethylamine dropwise, and keep warm for 0.5h after the addition is complete; turn off the heating, cool down (15~25℃ / h) to 2~8℃, keep warm for 0.5h, filter, and obtain about 25g of wet gentianic acid diethylamine salt; Free: Add 200g of water to the reactor and add wet gentianic acid diethylamine salt; under nitrogen protection, start stirring, control the temperature at 20~30℃, add concentrated hydrochloric acid dropwise to adjust the pH; cool down by 0~10℃, keep warm for 0.5h, filter, and obtain the wet gentianic acid refined product; Decolorization and crystallization: Add 250g of water, wet gentian acid concentrate, 0.2g of activated carbon, and 0.1g of oxalic acid to the reactor; under nitrogen protection, start stirring, heat to 65~75℃, keep warm for 0.5~1h, and filter while hot; cool the filtrate by 0~10℃ and keep warm for 0.5h. Filtration and drying: Rinse with water, then wash the filter cake with 22g of n-heptane. Dry the filter cake under vacuum at 40~55℃ for 12h to obtain 11g of high-purity gentianic acid.

[0090] Example 2 Feeding and reaction: Add 5.0 mol / L NaOH solution, 200 g of 5-bromosalicylic acid, 1.8 g of cuprous chloride, and 2 g of oxalic acid to the reactor; under nitrogen protection, start stirring; heat to 100~120℃ and react for 24 h; take samples for HPLC control (5-bromosalicylic acid) ≤1.5%; cool to room temperature (20~30℃) and add water; Acidification: Control the temperature at 20~30℃, add concentrated hydrochloric acid to adjust the pH of the reaction solution to 2.4, solid will precipitate out, then filter; Extraction: Add 200g of sodium chloride and 1000g of methyl tert-butyl ether to the filtrate, stir and extract, and flocculent matter will appear after standing. Filtration: Add 50g of diatomaceous earth to the Buchner funnel, filter, separate the liquid to obtain organic phase one and aqueous phase; add 500g of methyl tert-butyl ether to the aqueous phase, filter, separate the liquid to obtain organic phase two, and combine organic phase two with organic phase one to obtain organic phase three; Crystallization: Concentrate the organic phase under reduced pressure at 40-50℃ until a large amount of solid precipitates. Add 500g of n-heptane; stir for 1-2 hours, and filter at room temperature (20-30℃); dry the filter cake under vacuum at 40-50℃ for 2-4 hours to obtain 68g of crude gentianic acid. Salt formation: Add 450g of acetone and crude gentianic acid to the reaction vessel. Under nitrogen protection, start stirring. Control the temperature at 10~35℃ and add 150g of acetone solution containing 52.60g of diethylamine dropwise. After the addition is complete, keep the temperature for 0.5h. Turn off the heating and cool down (15~25℃ / h) to 2~8℃. Keep the temperature for 0.5h and filter to obtain 96g of wet diethylamine gentianic acid salt. Free: Add water and wet gentianic acid diethylamine salt to the reactor; under nitrogen protection, start stirring, control the temperature at 20~30℃, and add concentrated hydrochloric acid dropwise to adjust the pH; cool down by 0~10℃, keep warm for 0.5h, filter, and obtain the wet gentianic acid refined product; Decolorization and crystallization: Add 1000g of water, wet gentian acid product, 1g of activated carbon, and 0.5g of oxalic acid to the reactor; under nitrogen protection, start stirring, heat to 65~75℃, keep warm for 0.5~1h, and filter while hot; cool the filtrate by 0~10℃ and keep warm for 0.5h. Filtration and drying: Rinse with water, then wash the filter cake with 200g of n-heptane. Dry the filter cake under vacuum at 40~55℃ for 12.0h to obtain 48g of high-purity gentianic acid.

[0091] Example 3 Feeding and reaction: Add 5.0 mol / L KOH solution, 500 g of 5-bromosalicylic acid, 5.0 g of copper sulfate pentahydrate, and 5 g of oxalic acid to the reactor; under nitrogen protection, start stirring; heat to 100~120℃ and react for 24 h; take a sample for HPLC control (5-bromosalicylic acid) ≤1.5%; cool to room temperature (20~30℃) and add water; Acidification: Control the temperature at 20~30℃, add concentrated hydrochloric acid to adjust the pH of the reaction solution to 2.4, solid will precipitate out, then filter; Extraction: Add 500g of sodium chloride and 250g of methyl tert-butyl ether to the filtrate, stir and extract, and flocculent matter will appear after standing. Filtration: Add 50g of diatomaceous earth to the Buchner funnel, filter, separate the liquid to obtain organic phase one and aqueous phase; add 125g of methyl tert-butyl ether to the aqueous phase, filter, separate the liquid to obtain organic phase two, combine organic phase two with organic phase one to obtain organic phase three; Crystallization: Concentrate the organic phase under reduced pressure at 40-50℃ until a large amount of solid precipitates, add 250g of n-heptane; stir for 1-2 hours, filter at room temperature (20-30℃); dry the filter cake under vacuum at 40-50℃ for 2-4 hours to obtain 160g of crude gentianic acid. Salt formation: Add 1200g of acetone and crude gentianic acid to the reaction vessel. Under nitrogen protection, start stirring. Control the temperature at 10~35℃ and add 280g of acetone solution containing 131.50g of diethylamine dropwise. After the addition is complete, keep the temperature for 0.5h. Turn off the heating and cool down (15~25℃ / h) to 2~8℃. Keep the temperature for 0.5h and filter to obtain wet diethylamine gentianic acid salt. Free: Add 2000g of water to the reactor and add wet gentianic acid diethylamine salt; under nitrogen protection, start stirring, control the temperature at 20~30℃, add concentrated hydrochloric acid dropwise to adjust the pH; cool down by 0~10℃, keep warm for 0.5h, filter, and obtain the wet gentianic acid refined product; Decolorization and crystallization: Add 2000g of water, wet gentian acid concentrate, 3g of activated carbon, and 1.5g of oxalic acid to the reactor; under nitrogen protection, start stirring, heat to 65~75℃, keep warm for 0.5~1h, and filter while hot; cool the filtrate by 0~10℃ and keep warm for 0.5h. Filtration and drying: Rinse with water, then wash the filter cake with 400g of n-heptane. Dry the filter cake under vacuum at 40~55℃ for 12h to obtain 110g of high-purity gentianic acid.

[0092] Example 4 The difference between this embodiment and Example 3 is that, in the acidification step, the pH of the reaction solution is adjusted to 2.3.

[0093] Example 5 The difference between this embodiment and Example 3 is that, in the acidification step, the pH of the reaction solution is adjusted to 2.5.

[0094] Example 6 The difference between this embodiment and Embodiment 3 is that, in the acidification step, the pH of the reaction solution is adjusted to 2.1.

[0095] Example 7 The difference between this embodiment and Embodiment 3 is that, in the acidification step, the pH of the reaction solution is adjusted to 2.7.

[0096] Example 8 The difference between this embodiment and Example 3 is that, in the salt formation step, the molar ratio of diethylamine to 5-bromosalicylic acid is 0.75:1.

[0097] Example 9 The difference between this embodiment and Example 3 is that, in the salt formation step, the molar ratio of diethylamine to 5-bromosalicylic acid is 0.81:1.

[0098] Example 10 The difference between this embodiment and Example 3 is that, in the salt formation step, the molar ratio of diethylamine to 5-bromosalicylic acid is 0.7:1.

[0099] Example 11 The difference between this embodiment and Example 3 is that, in the salt formation step, the molar ratio of diethylamine to 5-bromosalicylic acid is 0.85:1.

[0100] Example 12 The difference between this embodiment and Embodiment 3 is that, in the decolorization and crystallization steps, the temperature is raised and kept at that temperature for 6 hours, and then filtered while hot.

[0101] The raw materials, reagents, reaction conditions, and test results of the obtained samples for each embodiment are listed in Table 1 below.

[0102] Table 1

[0103] The above description is merely a preferred embodiment of this application and is not intended to limit the application in any other way. Any person skilled in the art may make changes or modifications to the disclosed technical content to create equivalent embodiments. However, any simple modifications, equivalent changes, and modifications made to the above embodiments based on the technical essence of this application without departing from the scope of the technical solution of this application shall still fall within the protection scope of this application.

Claims

1. A high-purity gentianic acid, characterized in that, Its purity is ≥99.50%, and it comprises: gentian acid, salicylic acid, and impurity A, wherein impurity A has the structure shown in formula (I): Formula (I); Preferably, in the high-purity gentianic acid, the mass percentage of salicylic acid is ≤0.1%, and the mass percentage of impurity A is ≤0.1%. Preferably, the high-purity gentianic acid further comprises impurity B, wherein impurity B has the structure shown in formula (II): Formula (II); Preferably, in the high-purity gentianic acid, the mass percentage of impurity B is ≤0.1%.

2. The high-purity gentianic acid according to claim 1, characterized in that, It is prepared by a method including the following steps: Feeding reaction: 5-bromosalicylic acid is added to an inorganic alkaline solution for reaction; Acidification: Add concentrated hydrochloric acid to adjust the pH, precipitate the solid, and filter; Extraction: Add extractant one to the filtrate obtained from the acidification step, extract, and after standing, flocculent matter appears; Filtration: Filtration and separation are performed to obtain organic phase one and aqueous phase. Extractant two is added to the aqueous phase for extraction. Filtration and separation are performed again to obtain organic phase two. Organic phase two is combined with organic phase one to obtain organic phase three. Crystallization: Concentrate organic phase III to precipitate solid, add organic solvent I to obtain crude gentianic acid; Salt formation: Add crude gentianic acid to organic solvent II, and add dropwise a solution of organic solvent II containing an organic base to obtain wet gentianic acid organic base salt; Free: Add the wet product of gentianic acid organic base salt to water, add concentrated hydrochloric acid dropwise to adjust the pH, filter, and obtain the wet product of gentianic acid refining; Decolorization and crystallization: Add the wet product of gentianic acid concentrate and the decolorizing agent to water, filter, and obtain gentianic acid crystals; Filtration and drying: Gentian acid crystals were rinsed with water, then washed with an organic solvent, and dried to obtain high-purity gentian acid.

3. The high-purity gentianic acid according to claim 2, characterized in that, In the feeding reaction step, 5-bromosalicylic acid is added to an inorganic alkaline solution in the presence of a copper catalyst, stirred, heated to react the 5-bromosalicylic acid with the inorganic alkaline solution, cooled, and then water is added. Preferably, the inorganic alkaline solution is an aqueous solution of sodium hydroxide or an aqueous solution of potassium hydroxide, and more preferably an aqueous solution of potassium hydroxide. Preferably, the concentration of the inorganic alkaline solution is 4~8 mol / L, more preferably 5~6 mol / L; Preferably, the molar ratio of the inorganic base to 5-bromosalicylic acid is 4~7:1, more preferably 5~6:1; Preferably, the temperature is increased to 90~114℃, more preferably to 105~114℃; Preferably, the reaction of 5-bromosalicylic acid with an inorganic alkaline solution is carried out by heating, and the content of 5-bromosalicylic acid is controlled to be less than 1.5% in HPLC. The reaction time is 20-48 h, more preferably 20-30 h. Preferably, the temperature reduction is to 20~30℃; Preferably, 5-bromosalicylic acid is added to an inorganic alkaline solution in the presence of a copper catalyst and oxalic acid; more preferably, the molar ratio of oxalic acid to 5-bromosalicylic acid is 0.05~0.15:

1. Preferably, the copper catalyst is copper sulfate pentahydrate or cuprous oxide, more preferably copper sulfate pentahydrate; preferably, the molar ratio of copper sulfate pentahydrate to 5-bromosalicylic acid is 0.05~0.15:1; preferably, the molar ratio of cuprous oxide to 5-bromosalicylic acid is 0.025~0.075:

1. Preferably, the molar ratio of water to 5-bromosalicylic acid is 40-70:1, more preferably 50-60:

1.

4. The high-purity gentianic acid according to claim 2 or 3, characterized in that, During the acidification step, adjust the pH to 2.3-2.5; Preferably, concentrated hydrochloric acid is added at 20-30°C to adjust the pH.

5. The high-purity gentianic acid according to any one of claims 2 to 4, characterized in that, In the extraction step, the extractant is selected from any one or more of dichloromethane, ethyl acetate, isopropyl acetate, toluene, and methyl tert-butyl ether; Preferably, the extractant is methyl tert-butyl ether; Preferably, in the extraction step, extractant one and extraction aid are added to the filtrate obtained in the acidification step, wherein the extraction aid is preferably sodium chloride; Preferably, the mass ratio of methyl tert-butyl ether to 5-bromosalicylic acid is 4~6:1, more preferably 5~5.5:1; Preferably, the mass ratio of sodium chloride to 5-bromosalicylic acid is 1.0~1.5:1; Preferably, in the filtration step, the extractant is selected from any one or more of dichloromethane, ethyl acetate, isopropyl acetate, toluene, and methyl tert-butyl ether; Preferably, the mass ratio of the extractant to 5-bromosalicylic acid is 4~6:1, more preferably 5~5.5:1; Preferably, a filter aid is added to the funnel, and the mixture is filtered and separated to obtain an organic phase and an aqueous phase; more preferably, the filter aid is diatomaceous earth.

6. The high-purity gentianic acid according to any one of claims 2 to 5, characterized in that, In the crystallization step, organic phase three is concentrated, a solid is precipitated, organic solvent one is added, the mixture is stirred, filtered, and the filter cake is dried to obtain crude gentianic acid. Preferably, the organic solvent is selected from one or more of n-heptane, acetone, ethyl acetate, petroleum ether, and chloroform; Preferably, a large amount of solid is precipitated from the concentrated organic phase; Preferably, the organic phase III is concentrated under reduced pressure at 40~60°C, more preferably at 40~50°C; Preferably, the mass ratio of the organic solvent to 5-bromosalicylic acid is 4~5.5:1, more preferably 4.5~5:1; Preferably, the stirring time is 1-2 hours; Preferably, filtration is performed at 20~30℃; Preferably, the filter cake is vacuum dried at 40-50°C for 2-4 hours to obtain crude gentianic acid.

7. The high-purity gentianic acid according to any one of claims 2 to 6, characterized in that, In the salt formation step, crude gentianic acid is added to organic solvent II, stirred, and a solution of organic solvent II containing organic base is added dropwise. The mixture is then cooled and filtered to obtain wet gentianic acid organic base salt. Preferably, a solution of organic solvent II containing an organic base is added dropwise at a temperature of 10~35℃; Preferably, the organic base is diethylamine; Preferably, the molar ratio of the organic base to 5-bromosalicylic acid is 0.75~0.85:1; Preferably, the mass ratio of the organic solvent II to the crude gentian acid is 8.6~10:1, more preferably 9~9.8:1; Preferably, the organic solvent is selected from one or more of acetone, isopropanol, and tetrahydrofuran; Preferably, the temperature is reduced to 2-8°C.

8. The high-purity gentianic acid according to any one of claims 2 to 7, characterized in that, In the ionization step, the wet product of gentianic acid organic base salt is added to water, stirred, concentrated hydrochloric acid is added dropwise to adjust the pH, cooled, and filtered to obtain the wet product of gentianic acid refining. Preferably, concentrated hydrochloric acid is added dropwise at 20-30°C to adjust the pH. Preferably, the pH is adjusted to 1-2; Preferably, the mass ratio of water to the wet product of gentianic acid organic base salt is 4~6:1; Preferably, the cooling is reduced to 0~10℃.

9. The high-purity gentianic acid according to any one of claims 2 to 8, characterized in that, In the decolorization and crystallization steps, the wet product of gentianic acid and the decolorizing agent are added to water, stirred, heated, filtered, and the filtrate is cooled to obtain gentianic acid crystals; Preferably, the gentian acid refined product (wet), decolorizing agent, and oxalic acid are added to water; Preferably, the decolorizing agent is selected from one or more of activated carbon, alumina, and kaolin; Preferably, the temperature is maintained for 0.5 to 6 hours after heating, more preferably 0.5 to 4 hours, and even more preferably 0.5 to 1.5 hours. Preferably, the temperature is increased to 65~75°C; Preferably, the mass ratio of activated carbon to wet gentian acid concentrate is 0.05~0.1:1; Preferably, the mass ratio of the oxalic acid to the gentianic acid refined wet product is 0.01~0.03:1; Preferably, the mass ratio of water to the wet product of gentian acid is 4-6:1; Preferably, the solution is filtered and the filtrate is cooled to 0-10°C to obtain gentianic acid crystals.

10. The high-purity gentianic acid according to any one of claims 2 to 9, characterized in that, In the filtration and drying steps, the drying conditions are: 40~55℃, vacuum drying for 10~15h.

11. The use of high-purity gentianic acid according to any one of claims 1 to 10 in the preparation of antiviral agents, antibacterial agents, analgesics or antioxidant excipients.

Citation Information

Patent Citations

  • Process for production of hydroxybenzoic acids

    CN100363322C

  • Method for preparing high purity gentianic acid

    CN102766042A